Clinical trials: Diphtheria-Tetanus-acellular Pertussis Vaccines
Diphtheria, Tetanus
Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vaccine
The purpose of this study is to evaluate the long term immunogenicity produced in children by the investigational hexavalent vaccine (DTaP-IPV-Hep B-PRP-T) given in Study A3L15 (NCT 00362336).
- Conditions
- Diphtheria, Tetanus, Whooping Cough, Hepatitis B
- Trial name
- NCT01105559
- Where
- 2 sites in South Africa
- Volunteers
- 455 people, healthy volunteers welcome
- Sponsor
- Sanofi
Streptococcus Pneumoniae Infections
Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine
This clinical study aims to evaluate the mutual influence of combined administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine in the target population
- Trial name
- NCT06817187
- Testing
- 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed), Diphtheria, Tetanus and Acellular pertussis (Component) Combined Vaccine (Adsorbed)
- Where
- China
- Volunteers
- 1,110 people, healthy volunteers welcome
- Sponsor
- Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd
Acellular Pertussis, Diphtheria
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00346073
- Testing
- Boostrix™, ADACEL®
- Where
- 42 sites in United States
- Volunteers
- 2,337 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Bordetella Pertussis, Whooping Cough
Immunogenicity and Safety of BPZE1 Intranasal Pertussis Vaccine in Healthy School-age Children
This study evaluates the safety and immunogenicity of the BPZE1 live, attenuated pertussis vaccine, intended to prevent nasopharyngeal colonization and pertussis disease, and compares BPZE1 vaccine vs Boostrix vaccine vs both…
- Trial name
- NCT05116241
- Testing
- BPZE1 pertussis vaccine and Boostrix
- Where
- 16 sites in Australia, Costa Rica and 1 more
- Volunteers
- 368 people, healthy volunteers welcome
- Sponsor
- ILiAD Biotechnologies
Infections, Rotavirus
Prophylactic Antipyretic Treatment in Children Receiving Pneumococcal Conjugate and Standard Infant Vaccines
The purpose of this trial is to assess if the rate of febrile reactions following the co-administration of pneumococcal conjugate vaccines with standard infant vaccines is lowered when paracetamol is given prophylactically.
- Trial name
- NCT00370318
- Testing
- 10 valent pneumococcal conjugate vaccine, Infanrix Hexa, Rotarix
- Where
- 10 sites in Czechia
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib™) Vaccine
The purpose of this booster study is to evaluate the immune persistence in healthy Chinese subjects primed in study NCT01086423 with GSK Biologicals' Infanrix-IPV+Hib™ (DTPa-IPV/Hib) vaccine.
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Haemophilus Influenzae Type b
- Trial name
- NCT01449812
- Testing
- Infanrix+Hib™, Poliorix™
- Where
- 2 sites in China
- Volunteers
- 831 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children.
This phase 3b study will compare the immunogenicity and reactogenicity of the dTpa-IPV vaccine to that of a DTPa-IPV vaccine when administered as a booster dose in healthy children 5-6 years of age who have received three primary…
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Poliomyelitis
- Trial name
- NCT00871000
- Testing
- Boostrix Polio™ 711866, Priorix Tetra TM 208136, Tetravac TM
- Where
- 8 sites in Italy
- Volunteers
- 303 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Neisseria Meningitidis, Haemophilus Influenzae Type b
Primary & Booster Study in Infants to Demonstrate Non-inferiority, Persistence & Immunogenicity of Hib-MenC Vaccine
The purpose of this primary vaccination phase is to demonstrate the non-inferiority of two doses of Biologicals' Hib-MenC conjugate vaccine when given with Infanrix™ penta to infants (at 3 \& 5m) compared to NeisVac-C™ given with…
- Trial name
- NCT00327184
- Testing
- Haemophilus influenzae type b- and meningococcal serogroup C (vaccine), Infanrix Penta, Infanrix hexa
- Where
- 16 sites in Finland, Italy
- Volunteers
- 709 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Diphtheria
Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children
This protocol posting deals with objectives \& outcome measures of the booster phase. The objectives \& outcome measures of the primary phase are presented in a separate protocol posting (NCT number = NCT00412854).
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00696423
- Testing
- Infanrix™, Hiberix™
- Where
- 3 sites in China
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Acellular Pertussis, Tetanus
Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age
The purpose of this study is to show that the immunogenicity of newly formulated DTPa-HBV-IPV/Hib vaccine is as good as the immunogenicity of the currently licensed formulation of the vaccine.
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Hepatitis B
- Trial name
- NCT00376779
- Testing
- Infanrix hexa Vaccine
- Where
- 6 sites in Finland
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus
Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine
This study is a randomized, blinded, active-controlled phase I clinical trial to evaluate the safety and preliminary immunogenicity of the Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine (DTacP) in subjects…
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT06184542
- Testing
- DTacP (one-dose booster), DTacP (three-dose primary vaccination), DT (one-dose booster)
- Where
- 3 sites in China
- Volunteers
- 460 people, healthy volunteers welcome
- Sponsor
- Institute of Medical Biology, Chinese Academy of Medical Sciences
Diphtheria, Tetanus
Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS
The objective of this study is to assess the immunogenicity and safety of the DTaP-IPV combination vaccine compared with those of separate DTaP and IPV vaccines administered to healthy infants at 2, 4, and 6 months of age.
- Conditions
- Diphtheria, Tetanus, Pertussis, Poliomyelitis
- Trial name
- Venus (NCT02458183)
- Testing
- DTaP-IPV combination vaccine, DTaP vaccine and IPV vaccine
- Where
- 20 sites in South Korea, Thailand
- Volunteers
- 476 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Diphtheria, Acellular Pertussis
Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants
This study aims to estimate the risk factors associated with pertussis/whopping cough infection among infants less than one year of age in a United States (U.S.) commercially insured population.
- Conditions
- Diphtheria, Acellular Pertussis, Tetanus
- Trial name
- NCT01890850
- Testing
- Retrospective database study using administrative claims data
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Tetanus, Diphtheria
Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjects
This was a dose and formulation ranging study to assess the safety and immunogenicity of SP0173 in healthy adolescents, adults, and older adults in the United States (US).
- Conditions
- Tetanus, Diphtheria, Pertussis, Whooping Cough
- Trial name
- NCT02587520
- Testing
- Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2, Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3
- Where
- 20 sites in United States
- Volunteers
- 1,363 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acellular Pertussis, Tetanus
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058
The purpose of this study is to assess the efficacy and safety of repeating dTpa booster in adults 10 years after previous booster vaccination with dTpa in a previous clinical study (NCT01267058).
- Conditions
- Acellular Pertussis, Tetanus, Diphtheria, Diphtheria-Tetanus-acellular Pertussis Vaccines
- Trial name
- NCT00548171
- Testing
- Boostrix™
- Where
- Australia
- Volunteers
- 203 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Immunogenicity and Safety of Tetanus, Diphtheria and Mono Component Acellular Pertussis (TdaP) Vaccine in Comparison to Tetanus and Diphtheria (Td) Vaccine When Given as Booster Vaccinations to Adults
The clinical trial is a phase III, double-blind, randomised, controlled, multi-centre, clinical trial, on the immunogenicity and safety of TdaP vaccine in comparison to Td vaccine when given as a booster vaccination to adults who…
- Trial name
- NCT01033877
- Testing
- TdaP vaccine SSI, Td vaccine SSI
- Where
- 2 sites in Denmark
- Volunteers
- 802 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Tetanus, Diphtheria
Study of Adacel® Vaccine Administered to Persons 10 Years of Age
The purpose of study Td519 is to demonstrate that Adacel® vaccine (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed) is safe and immunogenic in persons 10 years of age.
- Conditions
- Tetanus, Diphtheria, Pertussis
- Trial name
- NCT01311557
- Testing
- Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed
- Where
- 34 sites in United States
- Volunteers
- 1,302 people, healthy volunteers welcome
- Sponsor
- Sanofi
Pertussis
Boostrix® Pregnancy Registry
The purpose of this Registry is to detect and describe any abnormal pregnancy outcomes, including teratogenicity, in females intentionally or unintentionally exposed to Boostrix during their pregnancies in the US.
- Trial name
- NCT02096276
- Testing
- Data collection
- Where
- United States
- Volunteers
- 1,517 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis
Clinical Trial of the Adsorbed Acellular Pertussis (Tricomponent) DTaP-Haemophilus Influenzae Type b (Conjugate)-ACYW135 Group Meningococcal (Conjugate) Combined Vaccine
This clinical trial is conducted in two parts. Part One employs a randomized, partially blinded, dose-escalation, partially active-controlled design. Part Two utilizes a randomized, blinded, placebo-controlled design.
- Conditions
- Diphtheria, Tetanus and Acellular Pertussis, Epidemic Meningitis, Haemophilus Influenzae Type B Infection
- Trial name
- NCT07203755
- Testing
- Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4), DTcP-Hib-MCV4, Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis (DTcP)
- Where
- China
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CanSino Biologics Inc.
Diphtheria-Tetanus-acellular Pertussis Vaccines
Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea
The purpose of this study is to collect safety information from pre-adolescents, adolescents and adults after Boostrix vaccination is administered according to the approved prescribing information in Korea.
- Trial name
- NCT01929291
- Testing
- Boostrix, Safety data collection
- Where
- South Korea
- Volunteers
- 682 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline